cycE/CCNE Cancer Research Results
cycE/CCNE, Cyclin E: Click to Expand ⟱
| Source: |
| Type: |
Cyclin E regulates multiple downstream molecules, such as the retinoblastoma susceptibility gene (RB1) and the transcription factor E2F.
Cyclin E (Cyclin E1 and Cyclin E2) is the key regulator of the late G1 → S-phase transition.
Cyclin E is a prognostic marker in breast cancer, its altered expression increased with the increasing stage and grade of the tumor.
Cyclin E is a regulatory protein that plays a critical role in the cell cycle, particularly in the transition from the G1 phase to the S phase. Its expression levels can significantly influence cancer progression and patient prognosis.
Cyclin E expression is frequently elevated in various cancers and is generally associated with poor prognosis. Its role in promoting cell cycle progression makes it a potential biomarker for tumor aggressiveness and patient outcomes.
|
Scientific Papers found: Click to Expand⟱
| - |
Review, |
Var, |
NA |
|
|
|
- |
in-vitro, |
Nor, |
BV2 |
|
|
|
ROS⇅, ROS↑, ER Stress↑, Ca+2↑, Apoptosis↑, eff↑, DR5↑, 12LOX↓, Cyt‑c↑, Casp7↑, Casp9↑, Casp3↑, cl‑PARP↑, TumCCA↑, cycE/CCNE↑, CDK4↓, cycD1/CCND1↓, VEGF↓, cMyc↓, Hif1a↓, NF-kB↓, BioEnh↑, BioEnh↑, P450↓, *Hif1a↓, *iNOS↓, *COX2↓, *VEGF↓, *ROS↓, *PI3K↓, *Akt↓,
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Stroke, |
NA |
|
|
|
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
*tumCV↓, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↑, *Bax:Bcl2↑, *Casp3↑, *Casp8↑, *Casp9↑, *cl‑PARP↑, *TumCCA↑, *P21↑, *cycE/CCNE↑, *cycA1/CCNA1↓, *CDK2↓,
| - |
in-vitro, |
Lung, |
H1299 |
|
|
|
- |
in-vitro, |
Lung, |
H460 |
|
|
|
TumCP↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↑, CDK6↑, P21↑, p27↑, ERK↓, MAPK↓,
AntiCan↑, antiOx↓, Apoptosis↓, TumCP↓, TumCCA↑, Risk↓, ROS↓, SOD↑, Catalase↑, GSTs↑, ARE↑, NRF2↑, cycD1/CCND1↓, cycE/CCNE↑, CDK2↑, p27↑, BAX↑, Bcl-2↓, P53↑, ChemoSen↑,
| - |
in-vitro, |
CRC, |
Caco-2 |
|
|
|
- |
in-vivo, |
Nor, |
HCEC 1CT |
|
|
|
TumCG↓, Glycolysis↓, PPP↓, ATP↑, PDH↑, Ca+2↝, TumCP↓, lactateProd↓, OCR↑, ECAR↓, *ECAR∅, *other?, cycE/CCNE↑, cycA1/CCNA1↑, TumCCA↑, cycD1/CCND1↑, OXPHOS↑,
Showing Research Papers: 1 to 6 of 6
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
antiOx↓, 1, ARE↑, 1, Catalase↑, 1, GSTs↑, 1, NRF2↑, 1, OXPHOS↑, 1, ROS↓, 1, ROS↑, 2, ROS⇅, 1, SOD↑, 1,
Mitochondria & Bioenergetics ⓘ
ATP↑, 1, OCR↑, 1,
Core Metabolism/Glycolysis ⓘ
12LOX↓, 1, cMyc↓, 2, ECAR↓, 1, Glycolysis↓, 1, lactateProd↓, 1, PDH↑, 1, PPP↓, 1,
Cell Death ⓘ
Apoptosis↓, 1, Apoptosis↑, 1, BAX↑, 2, Bcl-2↓, 2, Casp3↑, 1, Casp7↑, 1, Casp9↑, 1, Cyt‑c↑, 1, DR5↑, 1, MAPK↓, 1, p27↑, 2,
Protein Folding & ER Stress ⓘ
ER Stress↑, 1,
Autophagy & Lysosomes ⓘ
BNIP3↑, 1,
DNA Damage & Repair ⓘ
P53↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
CDK2↓, 1, CDK2↑, 1, CDK4↓, 3, cycA1/CCNA1↑, 1, cycD1/CCND1↓, 4, cycD1/CCND1↑, 1, CycD3↓, 1, cycE/CCNE↑, 5, P21↑, 1, TumCCA↑, 5,
Proliferation, Differentiation & Cell State ⓘ
ERK↓, 1, TumCG↓, 1,
Migration ⓘ
Ca+2↑, 1, Ca+2↝, 1, TumCP↓, 3,
Angiogenesis & Vasculature ⓘ
Hif1a↓, 2, VEGF↓, 2,
Immune & Inflammatory Signaling ⓘ
NF-kB↓, 2,
Hormonal & Nuclear Receptors ⓘ
CDK6↑, 1,
Drug Metabolism & Resistance ⓘ
BioEnh↑, 2, ChemoSen↑, 1, eff↑, 1, P450↓, 1,
Functional Outcomes ⓘ
AntiCan↓, 1, AntiCan↑, 1, Risk↓, 1,
Total Targets: 60
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
Ferroptosis↓, 1, lipid-P↓, 1, NRF2↑, 1, ROS↓, 1, ROS↑, 1,
Mitochondria & Bioenergetics ⓘ
MMP↓, 1,
Core Metabolism/Glycolysis ⓘ
ALAT↓, 1, p‑AMPK↑, 1, ECAR∅, 1,
Cell Death ⓘ
Akt↓, 1, Apoptosis↓, 1, BAX↓, 1, Bax:Bcl2↑, 1, Casp3↑, 1, Casp8↑, 1, Casp9↑, 1, Fas↓, 1, Fas↑, 1, Ferroptosis↓, 1, iNOS↓, 2,
Transcription & Epigenetics ⓘ
other?, 1, tumCV↓, 1,
DNA Damage & Repair ⓘ
P53↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
CDK2↓, 1, cycA1/CCNA1↓, 1, cycE/CCNE↑, 1, P21↑, 2, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
PI3K↓, 1,
Angiogenesis & Vasculature ⓘ
Hif1a↓, 1, NO↓, 1, VEGF↓, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 2, PGE2↓, 1,
Clinical Biomarkers ⓘ
ALAT↓, 1, AST↓, 1,
Functional Outcomes ⓘ
cardioP↑, 1, cognitive↑, 1, hepatoP↑, 1, neuroP↑, 2, RenoP↑, 1,
Total Targets: 42
Scientific Paper Hit Count for: cycE/CCNE, Cyclin E
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:378 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid
Home Page